Today: 9 November 2025
Subscribe
Browse Category

Analyst Ratings News 15 October 2025 - 8 November 2025

Qualys (QLYS) Today — Nov 8, 2025: Analyst Upgrade Follows Q3 Beat; Guidance Raised as Stock Hovers Near $150

Qualys (QLYS) Today — Nov 8, 2025: Analyst Upgrade Follows Q3 Beat; Guidance Raised as Stock Hovers Near $150

Qualys, Inc. (NASDAQ: QLYS) is ending the week with fresh analyst attention after posting a stronger‑than‑expected third quarter and raising full‑year guidance earlier this week. As of today, one outlet reports an upgrade to Buy while another highlights lifted EPS forecasts, keeping the cybersecurity name on radar for Google News and Discover readers tracking post‑earnings momentum. The shares are trading around the $150 mark. MarketBeat+1 What’s new today (Nov 8, 2025) Bottom line for Nov 8: The weekend headlines extend a favorable post‑earnings narrative built on raised guidance and improving profitability metrics. Earnings recap: Q3 FY2025 at a glance Qualys
8 November 2025
 ·  ·  ·  ·  · 
Breaking: Eos Energy & MN8 Secure Huge 750 MWh U.S. Battery Storage Deal – Are Stocks Set to Skyrocket?

Eos Energy (EOSE) News Today: Price Target Uplift, Fresh Downgrade, and 70% Warrant Surge — What’s Moving the Stock (Nov 8, 2025)

Updated: November 8, 2025 Key takeaways What’s new today (Nov. 8, 2025) Downgrade lands after the run-up. MarketBeat carried an alert that Wall Street Zen cut EOSE to “Sell” early Saturday, noting the stock’s sharp appreciation and summarizing the existing split in coverage (a mix of Buy/Hold/Sell ratings and an average target near the low teens). While not a bulge-bracket call, the downgrade adds a counterweight to bullish revisions that followed earnings. MarketBeat Fresh transcript color: cash, guidance, and warrants. A newly posted Q3 2025 earnings call transcript highlights management’s stance that execution into Q4 supports the low end of
8 November 2025
 ·  ·  ·  · 
UnitedHealth Group Stock Surges Amid Analyst Upgrades: Is Wall Street Turning Bullish on UNH in 2025?

UnitedHealth (UNH) Premarket: Analysts Bullish on Comeback Despite 2025 Woes – What to Watch Nov. 3, 2025

UnitedHealth’s volatile 2025 has made UNH a headline story heading into Nov. 3 trading. After a surprise earnings miss in Q1 and a CEO shakeup this spring, UNH plunged to four-year lows. In late Oct. the turnaround narrative got a boost: Q3 beat estimates and management raised guidance gurufocus.com gurufocus.com. CEO Stephen Hemsley (back at the helm) told investors he’s confident “we will return to solid earnings growth next year” thanks to “operational rigor and more prudent pricing” reuters.com. Guggenheim and Reuters note Hemsley’s comeback has reassured investors and even prompted Buffett to buy in reuters.com reuters.com. Market analysts are increasingly
2 November 2025
 ·  ·  ·  · 
Visa (V) Stock Poised for a Surge? Crypto Pilot and Travel Deals Fuel Optimism

Visa Stock Jumps on Earnings Beat and Dividend Hike – Analysts Bullish on $400 Target

Visa’s Stock Rallies After Earnings and Dividend Hike Visa’s latest earnings report delivered plenty for investors to cheer. The company’s fiscal fourth-quarter results (for the quarter ended September 30, 2025) beat expectations on both the top and bottom line. Net revenues grew 12% year-over-year to $10.72 billion, slightly above consensus forecasts around $10.6 billion timesunion.com. Adjusted earnings came in at $2.98 per share, just topping analysts’ $2.97 estimate timesunion.com and up from $2.71 a year ago. This strong finish to the year reflected healthy consumer payment volumes and improved cross-border travel spending, even as the company had maintained cautious guidance in prior
28 October 2025
 ·  ·  ·  ·  · 
Clover Health (CLOV) Stock Soars 18% on Analyst Upgrades, Unusual Options Buzz

Clover Health (CLOV) Stock Soars 18% on Analyst Upgrades, Unusual Options Buzz

Stock Performance: Clover Health stock has been exceptionally volatile in mid‑October 2025. On Oct. 21 it jumped ~8.7% intraday to ~$3.20 marketbeat.com (from $2.92 prior close), and on Oct. 24 it spiked another ~18%, trading near $3.79 (from $3.20 close on Oct. 23) reuters.com. According to Reuters data, that surge propelled CLOV close to its 52-week high (~$4.87) and far above its recent 50‑day moving average (around $2.82) marketbeat.com. The 200-day average (~$3.02) was also eclipsed, signaling strong upward momentum marketbeat.com. This rally has come on unusually heavy volume (15+ million shares traded on Oct. 24 vs. a 3‑month average
24 October 2025
 ·  ·  ·  ·  · 
Sunrun (RUN) Stock Soars 5% to 12-Month High on Analyst Upgrades and Solar Incentives

Sunrun (RUN) Stock Soars 5% to 12-Month High on Analyst Upgrades and Solar Incentives

Stock Rallies on Upbeat Sentiment On Oct. 21, 2025, Sunrun (Nasdaq: RUN) traded around $20.50, up about 5% intraday reuters.com. This surge followed news that Wall Street’s Citigroup had upgraded Sunrun to “Buy” with a $26 price target marketbeat.com. The stock’s rally pushed it above the consensus 12-month analyst target (~$20) ts2.tech. In fact, RUN hit a new 12-month high (~$20.25) on Oct. 7 markets.financialcontent.com, as investors cheered its improving fundamentals and solar incentives. Over the year, Sunrun has been on a tear. Earlier in 2025, the shares languished near multi-year lows (around $5.38), but rallied into the teens after
21 October 2025
 ·  ·  ·  ·  · 
iBio Stock Surges on Bullish Analyst Calls and Obesity Drug Breakthroughs

iBio Stock Surges on Bullish Analyst Calls and Obesity Drug Breakthroughs

IBIO Stock Price and Recent Volatility As of midday October 21, 2025, iBio’s stock (NASDAQ: IBIO) trades around $0.89 per share marketbeat.com. The price has been volatile in recent days. Last week, shares jumped over 20% in pre-market trading on October 17 after Leerink Partners issued a bullish initiation, although the stock later settled near $0.85 by that day’s close marketbeat.com. Even with these upticks, iBio’s stock remains well below its levels earlier this year – it began 2025 at ~$2.45 and has declined about 63% year-to-date marketbeat.com. This underperformance comes amid broader small-cap biotech volatility; by comparison, the biotech
21 October 2025
 ·  ·  ·  · 
Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Ticker: Beam Therapeutics (NASDAQ: BEAM) globenewswire.com. – Price (Oct 21, 2025): ~$30 per share (about +17% recently) ts2.tech. – Sector: Biotechnology (precision gene editing) globenewswire.com. – Recent News: FDA granted Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations to Beam’s lead programs (BEAM-101 for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency) globenewswire.com stocktitan.net. Early trial data for these programs have been promising. – Analyst Outlook: Consensus is “Moderate Buy” with average 1-year target ~$45–46 marketbeat.com nasdaq.com, implying roughly 70–80% upside. Beam’s stock jumped sharply after the FDA awarded priority designations to its gene-editing therapies. On Oct 20,
21 October 2025
 ·  ·  ·  ·  · 
SoFi’s Roller-Coaster Rally: Fintech Stock Soars 230% in 2025 – What’s Next for SOFI?

SoFi Stock Surges on Analyst Upgrade and $1.6 Trillion Fintech Opportunity

Stock Rebound After Volatile Weeks SoFi’s stock has been on a roller-coaster. After tripling in the past year, climbing from single-digit prices to a record ~$30 in late September, the fintech favorite hit turbulence ts2.tech. In the final weeks of September and into early October, profit-taking and broader market jitters knocked SOFI off its highs. The shares slid about 10–15% from their peak, even logging a 5% one-day drop on Oct. 16 to around $26.60 ts2.tech. “Most buyers are already in,” one analyst quipped during the pullback – cautioning that the pool of new investors willing to propel the stock
20 October 2025
 ·  ·  ·  ·  · 
Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Stock Jumps as Outlook Brightens Gilead’s share price has been on a tear in recent weeks, reaching new highs for 2025. By mid-day October 17, GILD was up about 4.7% to roughly $123 per share benzinga.com. Year-to-date, the stock has rallied nearly 47%, adding tens of billions to Gilead’s market value stockanalysis.com. This far outpaces the single-digit gain of the Nasdaq Biotechnology Index over the same period stockanalysis.com invesco.com. Investors have cheered a string of positive catalysts: strong earnings, a fortified HIV franchise, and growing pipeline prospects. Notably, Gilead’s Q2 results in August beat expectations and prompted management to raise
17 October 2025
 ·  ·  ·  · 
Broadcom’s $10B AI Chip Deal Ignites Stock Surge – What’s Powering This Tech Giant’s Boom

Broadcom (AVGO) Stock Soars After $10B OpenAI AI Chip Deal – Analysts Raise Targets

Stock Performance and Recent Movement Broadcom’s stock has surged dramatically in 2023–2025, fueled by the AI boom and strategic deals ts2.tech. After a 10-for-1 split in Feb 2024, retail interest surged along with its fundamentals ts2.tech. By Oct 2025, Broadcom’s market cap surpassed $1.5 trillion ts2.tech. The share price peaked around $374 in early Sept 2025 (post-split), roughly double its level a year prior ts2.tech. Even after an early-October dip (amid broader market volatility), AVGO remains up ~70% YTD ts2.tech, far outperforming the S&P 500. Over the past week, the stock was volatile. On Oct 13 AVGO jumped +9.9% investing.com following
17 October 2025
 ·  ·  ·  ·  · 
Lockheed Martin News Roundup (Oct 1–10, 2025): Defense Giant Navigates New Contracts, Space Ambitions, and Market Momentum

Lockheed Martin (LMT) Stock Rises on $11B Navy Contract, Dividend Hike & Analyst Upgrades

Stock Performance Today and Recent Trend Lockheed’s stock opened around $504.8 on Oct. 15, 2025 and is roughly flat on the day marketbeat.com. Over the past week it has seen minor fluctuation but remains in a broad trading range. After falling as low as ~$410 in mid-July (post-Q2 earnings), LMT has rebounded over 20% and is now about 18% below its 52-week high benzinga.com marketbeat.com. Volume remains healthy and trading above its 50-day/200-day averages, reflecting continued investor interest. Despite some recent volatility, analysts note that LMT has strong governmental support. “Lockheed Martin makes 97% of its revenue from the U.S.
15 October 2025
 ·  ·  ·  ·  · 
1 2
Go toTop